{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:36:05Z","timestamp":1784874965701,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>In the past, immune checkpoint inhibitors (ICIs) like camrelizumab have been associated with rheumatic immune-related adverse events (irAEs).To prevent serious adverse consequences, early diagnosis of rheumatic irAEs is crucial. A 40-year-old patient with malignant melanoma experienced severe hypokalemia and fatigue after 6 months of camrelizumab therapy, which was unresponsive to potassium chloride supplementation. Subsequently, the patient was diagnosed with refractory hypokalemia secondary to type I renal tubular acidosis (RTA). After treatment with potassium citrate and hydroxychloroquine, blood potassium, chloride, carbon dioxide binding capacity, and arterial blood gases returned to normal and the fatigue symptoms disappeared. However, severe hypokalemia and fatigue returned following resumption of camrelizumab therapy, and only resolved upon discontinuation and intensified symptomatic treatment. No recurrence of the condition was observed after camrelizumab was discontinued. Refractory hypokalemia and RTA were attributed to undifferentiated connective tissue disease (UCTD), a rheumatic condition considered as an adverse event of camrelizumab. This case underscores the necessity of monitoring serum potassium levels during ICI therapy and the consideration of RTA and autoimmune diseases in cases of hypokalemia to prevent serious adverse consequences.<\/jats:p>","DOI":"10.3389\/fonc.2024.1442605","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:11:11Z","timestamp":1732597871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Yinfang","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13346","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","volume":"17","author":"Zhong","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1363","article-title":"Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial","volume":"9","author":"Mao","year":"2023","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/life13040877","article-title":"Rheumatic diseases development in patients treated by anti-PD1 immune checkpoint inhibitors: A single-centre descriptive study","volume":"13","author":"Ceccarelli","year":"2023","journal-title":"Life (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomized, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study\u00a0of 193\u00a0Japanese patients","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.027","article-title":"Apatinib combined with camrelizumabin advanced acral melanoma patients: An open-label, single-arm phase 2 trial","volume":"182","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase ib study of pembrolizumab as second-line therapy for chinese patients with advanced or metastatic melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0009","article-title":"Mechanisms in Endocrinology: Hypophysitis: diagnosis and treatment","volume":"179","author":"Joshi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B17","volume-title":"Renal Tubular Acidosis, 2017, no. Merck Manual Professional Version","author":"Hechanova","year":"2017"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103356","DOI":"10.1016\/j.autrev.2023.103356","article-title":"Autoantibodies testing in autoimmunity: Diagnostic, prognostic and classification value","volume":"22","author":"Sciascia","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.7333","article-title":"Neoadjuvant dual checkpoint inhibitors vs anti-PD1 therapy in high-risk resectable melanoma: A pooled analysis","volume":"10","author":"Mangla","year":"2024","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000023430.92674.E5","article-title":"Renal tubular acidosis: the clinical entity","volume":"13","author":"Rodr\u00edguez Soriano","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V32264","article-title":"Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren\u2019s syndrome and distal renal tubular acidosis","volume":"3","author":"Cohen","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5063405","DOI":"10.1155\/2017\/5063405","article-title":"Hypokalemic paralysis secondary to immune checkpoint inhibitor therapy","volume":"2017","author":"Balakrishna","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2020.05.015","article-title":"Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-A report of 3 cases","volume":"2","author":"Herrmann","year":"2020","journal-title":"Kidney Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8408015","DOI":"10.1155\/2018\/8408015","article-title":"Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy","volume":"2018","author":"El Bitar","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2370327","article-title":"Sicca syndrome\/Sj\u00f6gren\u2019s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management","volume":"20","author":"Pasoto","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7896749","DOI":"10.1155\/2019\/7896749","article-title":"Ipilimumab- and nivolumab-induced colitis causing severe hypokalemia and QTc prolongation","volume":"2019","author":"Anson","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz051","article-title":"A new expression of immune checkpoint inhibitors\u2019 renal toxicity: when distal tubular acidosis precedes creatinine elevation","volume":"13","author":"Charmetant","year":"2020","journal-title":"Clin Kidney J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1442605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:11:15Z","timestamp":1732597875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1442605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":32,"alternative-id":["10.3389\/fonc.2024.1442605"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1442605","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"article-number":"1442605"}}